According to current Guidelines for the treatment of Traumatic brain injury (TBI) (Brain Trauma Foundation, 2017), it is recommended that Intracranial pressure (ICP) and Cerebral perfusion pressure (CPP) be maintained within certain statistically generalized limits and not within the individual patient’s optimal limits, regardless of the specific characteristics of the patient and his or her injury. Despite the rapid development of medical technology, such treatment based solely on maintaining ICP and CPP values at statistically average critical limits does not allow to improve the outcome of severe TBI patients, and their mortality remains high (approximately 30%).
One of the major causes of ineffective treatment of TBI patients is that the generalized critical limits for ICP and CPP in the TBI Treatment Guidelines are not optimal for the treatment of each individual patient, when the tolerance reserve of intracranial pressure-volume changes in an individual patient is not known.
In order to improve treatment outcomes for TBI patients, it is essential to include monitoring of physiological parameters that allow to tailor the treatment to the TBI patients in clinical monitoring and therapy procedures. Such parameter is intracranial compliance (ICC), representing the reserves of volume expansion of intracranial components, avoiding an increase in ICP.
Without knowing the value of an individual patient’s ICC parameter, it is unclear how a patient can tolerate ICV and ICP changes, and what is the critical limit for the patient’s ICP, above which the brain cells will be irreversibly damaged.
As a solution to this problem, we propose a patentable innovative idea for non-invasive ICC measurement based on ultrasound measurement of the changes in optic nerve subarachnoid space (ONSS) and non-invasive induction of intracranial volume increase.
Via the R&D activities during the project, we will seek to develop and validate in clinical study our innovative non-invasive ICC measurement method. Today, the global market for such product is worth EUR 1.16 billion and it is predicted that the market for ICP measurement and monitoring technologies will reach EUR 2 billion by 2024.
This research project is funded by the European Regional Development Fund according to the 2014–2020 Operational Programme for the European Union Funds’ Investments, under measure’s No. 01.2.2-LMT-K-718 activity “Research Projects Implemented by World-class Researcher Groups to develop R&D activities relevant to economic sectors, which could later be commercialized”.
Period of project implementation: 2020-10-01 - 2023-08-31
Project coordinator: Kaunas University of Technology
Project partners: VŠĮ Vilniaus universiteto ligoninės Santaros klinikos